Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Imrie

Showing results (41-50 of 45) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 45 results.
Annals of Internal Medicine|September 1, 1995
Isolated chloroma: the effect of early antileukemic therapyK R Imrie, M J Kovacs, D Selby, et al.
Hematological Oncology|May 1, 2018
Management of newly diagnosed high-risk and intermediate-risk follicular lymphoma with <sup>90</sup> Y ibritumomab tiuxetan in a phase II studyNeil L Berinstein, Nancy M Pennell, Rashmi Weerasinghe, et al.
Annals of Hematology|January 9, 2015
Prolonged clinical remissions in patients with relapsed or refractory follicular lymphoma treated with autologous stem cell transplantation incorporating rituximabN L Berinstein, S Bhella, N M Pennell, et al.
Journal of the National Cancer Institute|April 15, 2015
Gemcitabine/dexamethasone/cisplatin vs cytarabine/dexamethasone/cisplatin for relapsed or refractory aggressive-histology lymphoma: cost-utility analysis of NCIC CTG LY.12Matthew C Cheung, Annette E Hay, Michael Crump, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 1, 2014
Randomized comparison of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin chemotherapy before autologous stem-cell transplantation for relapsed and refractory aggressive lymphomas: NCIC-CTG LY.12Michael Crump, John Kuruvilla, Stephen Couban, et al.
Pageof 5

Showing results (41-50 of 45) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 45 results.
Annals of Internal Medicine|September 1, 1995
Isolated chloroma: the effect of early antileukemic therapyK R Imrie, M J Kovacs, D Selby, et al.
Hematological Oncology|May 1, 2018
Management of newly diagnosed high-risk and intermediate-risk follicular lymphoma with <sup>90</sup> Y ibritumomab tiuxetan in a phase II studyNeil L Berinstein, Nancy M Pennell, Rashmi Weerasinghe, et al.
Annals of Hematology|January 9, 2015
Prolonged clinical remissions in patients with relapsed or refractory follicular lymphoma treated with autologous stem cell transplantation incorporating rituximabN L Berinstein, S Bhella, N M Pennell, et al.
Journal of the National Cancer Institute|April 15, 2015
Gemcitabine/dexamethasone/cisplatin vs cytarabine/dexamethasone/cisplatin for relapsed or refractory aggressive-histology lymphoma: cost-utility analysis of NCIC CTG LY.12Matthew C Cheung, Annette E Hay, Michael Crump, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 1, 2014
Randomized comparison of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin chemotherapy before autologous stem-cell transplantation for relapsed and refractory aggressive lymphomas: NCIC-CTG LY.12Michael Crump, John Kuruvilla, Stephen Couban, et al.
Pageof 5